Presentations Presentations Report of Organizational Actions Affecting Basis of Securities Supplement to Dividend FAQ STI - Dividend FAQ January 2023 Corporate Presentation Sorrento STI-9167 and STI-9199 anti-Omicron Neutralization Antibody Abivertinib November 2021 STI mRNA COVID Vaccine Program August 2021 Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain, at the 14th Annual Pain Therapeutics Summit held virtually from September 21, 2020 Tools Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Presentations Report of Organizational Actions Affecting Basis of Securities Supplement to Dividend FAQ STI - Dividend FAQ January 2023 Corporate Presentation Sorrento STI-9167 and STI-9199 anti-Omicron Neutralization Antibody Abivertinib November 2021 STI mRNA COVID Vaccine Program August 2021 Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain, at the 14th Annual Pain Therapeutics Summit held virtually from September 21, 2020
Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain, at the 14th Annual Pain Therapeutics Summit held virtually from September 21, 2020
